The FreeStyle Libre system

Making a real-world impact

Real-world use of the FreeStyle Libre system in Canada1

""

Use of the FreeStyle Libre family of products is clinically proven to significantly reduce A1C in patients with T2D2,3† 

 

 

Patients with T2D on long-acting insulin saw significant A1C reductions2†‡

0.6% A1C reduction

Patients with T2D on non-insulin therapies saw significant reductions in A1C2†§

0.9% A1C reduction

Patients with T2D and poor glycemic control saw significant A1C reductions3†¶

1.38% A1C reduction

Continuing health education

Explore upcoming virtual educational events.

""

GLP-1=glucagon-like peptide 1; NPH=neutral protamine Hagedorn; T1D=type 1 diabetes; T2D=type 2 diabetes.

* For diabetes patients using insulin more than once a day. For individuals with T2D on once-daily insulin in addition to non-insulin antihyperglycemic agents, testing at least once a day at variable times is recommended. For individuals with T2D not receiving insulin therapy, frequency of glucose testing recommendations should be individualized depending on type of antihyperglycemic agents, level of glycemic control and risk of hypoglycemia.4

† Data from this study were collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system with optional real-time glucose alarms. Therefore, the study data are applicable to both products.

‡ Real-world data on change in A1C in patients with T2D taking long-acting insulin therapy after use of the FreeStyle Libre system for 6 months (n=277) and 12 months (n=87). In the 12-month group, patients using the FreeStyle Libre system demonstrated significant A1C reduction of 0.5% (p=0.0014).

§ Real-world data on change in A1C in patients with T2D taking non-insulin therapies (oral agents, GLP-1 receptor agonists) after use of the FreeStyle Libre system for 6 months (n=497) and 12 months (n=120). In the 12-month group, patients using the FreeStyle Libre system demonstrated significant A1C reduction of 0.7% (p<0.0001).

¶ Real-world data on change in A1C in 1,183 patients with T2D and poor glycemic control not on bolus insulin after use of the FreeStyle Libre system for 6 months.

 

References:

1.      Berard L, et al. Canadian real-world analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB.

2.      Miller E, et al. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: 80th Scientific Sessions of the American Diabetes Association: June 12-16, 2020; Virtual.

3.      Wright E, et al. HbA1c reduction associated with a FreeStyle Libre system in people with type 2 diabetes not on bolus insulin therapy [78-LB]. Poster presented at: 80th Scientific Sessions of the American Diabetes Association: June 12-16, 2020; Virtual.

4.      Berard LD, et al. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: monitoring glycemic control. Can J Diabetes 2018;42(suppl 1):S47-53.

Cookie Policy

FreeStyle Libre uses cookies to give you the best possible service. By using our website, you consent to the use of cookies. 

Data protection

This site is intended for Healthcare Professionals only. Visit patient site.

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert. 

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.